Bubs Australia (BUB) Status update summary
Event summary combining transcript, slides, and related documents.
Status update summary
29 Mar, 2026Strategic direction and leadership
Introduced a highly experienced executive team, reinforcing a disciplined, values-driven culture and global expertise.
Outlined a clear five-year strategy focused on brand activation, portfolio expansion, and supply chain excellence.
Emphasized a capital-light, asset-light business model with operational leverage and global agility.
Strong governance, financial discipline, and a proven track record of revenue and profit growth underpin value creation.
Leadership team diversity and expertise positioned to drive execution, transformation, and performance culture.
Market positioning and growth opportunities
Focused on premium infant nutrition, leveraging Australian heritage, clean label credentials, and strong brand equity.
Premium segments in Australia, U.S., and China are outpacing mass-market growth, with goat formula mainstreaming and premium natural segment growing rapidly.
U.S. business rapidly scaling, targeting 10,000 retail doors and top-3 premium natural IMF and top-2 goat IMF positions.
China strategy leverages e-commerce, physical retail, digital KOLs, and expansion into tier 2/3 cities and general trade.
Disciplined expansion planned for Canada, Mexico, and Vietnam, focusing on premium-led, scalable markets with high category participation.
Financial outlook and operational execution
Upgraded FY26 revenue guidance to $120–125 million, with underlying EBIT/EBITDA of $9–11 million and 1H FY26 EBITDA at $4.4 million.
Achieved 26% revenue CAGR over three to four years, with ambitions for continued double-digit growth and strong operating leverage.
Capital-light approach maintained; significant inventory build to support growth, aiming for OCF positivity by FY27.
Operational excellence and integrated business planning prioritized to avoid past inventory write-offs.
Air freight and tariffs impacting short-term margins, but managed within guidance.
Latest events from Bubs Australia
- Revenue up 14% to $55.5M, led by US growth; gross margin 48%; FY26 outlook upgraded.BUB
H1 202627 Feb 2026 - Revenue up 34% to $80m, with strong US/China growth and positive FY2025 outlook.BUB
H2 202423 Jan 2026 - Strong growth, margin gains, and US/China expansion set up for FY25 profitability.BUB
AGM 202413 Jan 2026 - Net profit of AUD 3.6M and 23% revenue growth, but FDA and funding risks remain.BUB
H1 20253 Dec 2025 - Revenue up 29% to $102.5M, USA leads growth, positive EBITDA, and FDA submission for US access.BUB
H2 202523 Nov 2025 - Strong FY25 growth, global expansion, and strategic focus on FDA and China drive outlook.BUB
AGM 202520 Nov 2025 - Net revenue up 30% to $25.6m, EBITDA positive, and $22.9m in liquidity at quarter end.BUB
Q1 2026 TU30 Oct 2025 - FY25 saw 29% revenue growth, positive EBITDA, and strong US and China market performance.BUB
Q4 2025 TU28 Jul 2025